The Medical Developments International Ltd (ASX:MVP) share price is jumping higher on Monday following the release of a presentation…
The post The Medical Developments International (ASX:MVP) share price is jumping 7% today appeared first on The Motley Fool Australia. –
The Medical Developments International Ltd (ASX: MVP) share price has been a strong performer on Monday.
In afternoon trade, the medical device company’s shares are up 7% to $5.37.
Why is the Medical Developments International share price charging higher?
Investors have been buying Medical Developments International shares on Monday following the release of a roadshow presentation.
Within the presentation, the company acknowledged that current results are challenging because of COVID-19 but notes that it is investing for the future.
In respect to its results, Medical Developments International recently posted a sharp reduction in profit during the first half of FY 2021.
This was driven partly by lower sales of Penthrox, also known as the green whistle, due to COVID-19 causing a reduction in trauma-related events.
Positively, management is anticipating a rebound in sales in the second half. This is due to the easing of COVID-19 restrictions and increased community movement.
What about the future?
The company also revealed that a number of initiatives are currently in-flight.
This includes the analysis of European market access routes to growth and an organisational review to position the company for rapid growth.
In respect to Europe, management notes that there are encouraging early signs of growth in Europe. This includes, in some cases, building from the ground level after almost two years of partner inactivity.
It is also targeting new European country launches in key markets in 2021, along with potential new partnerships.
Longer term opportunities
The company also provided an update on its longer term opportunities.
It notes that it had a positive exchange with the US FDA at its Type-C meeting in January. It is now awaiting the final post-meeting note regarding its path forward in the lucrative market.
In addition to this, a phase one Pharmaco-Kinetic study in China will begin to enrol patients in the third quarter of 2021.
The company also has phase three Trauma and Procedural studies in China that are planned to commence in the not so distant future.
And finally, Medical Developments International is continuing with the CSIRO to develop alternative manufacturing methods for generic active pharmaceutical ingredients (APIs) utilising its continuous flow platform technology.
It advised that advancements have been made in late-stage Lidocaine scale-up development. The company plans to advance four additional APIs into scale-up phase during 2021.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Why the Queensland Pacific Metals (AXS:QPM) share price is climbing today
- Up almost 1000% in 1 year, the Bionomics (ASX:BNO) share price moves higher
- Treasury Wine (ASX: TWE) share price shoots over 8% higher on takeover talks
- ANZ (ASX:ANZ) hits 3 year high. Can we thank dividends?
- Don’t take it from me. Take it from them…
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.